Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05618925 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 1, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Mar 15, 2026 to May 15, 2026v11
  2. Start date changed from estimate of Nov 1, 2024 to Aug 22, 2025 Study sites: 1 to 2v10 Show 1 more changeShow less
    • Study sites: 1 to 2
  3. Start date: Jun 30, 2024 to Nov 1, 2024v9
  4. Trial status: Not Yet Recruiting to Recruiting Start date: Apr 30, 2024 to Jun 30, 2024 · Site details revisedv8 Show 2 more changesShow less
    • Start date: Apr 30, 2024 to Jun 30, 2024
    • Site details revised
  5. Start date: Mar 15, 2024 to Apr 30, 2024v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Sep 29, 2024 to Mar 15, 2026 Start date: Nov 1, 2023 to Mar 15, 2024 · Completion date: Sep 29, 2026 to Mar 15, 2027 · Eligibility criteria shortened, about 22 words · 1 morev6 Show 4 more changesShow less
    • Start date: Nov 1, 2023 to Mar 15, 2024
    • Completion date: Sep 29, 2026 to Mar 15, 2027
    • Eligibility criteria shortened, about 22 words
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  2. Start date: Sep 1, 2023 to Nov 1, 2023v5
  3. Start date: Apr 15, 2023 to Sep 1, 2023 Eligibility criteria expanded, about 26 wordsv4 Show 1 more changeShow less
    • Eligibility criteria expanded, about 26 words

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Mar 15, 2023 to Apr 15, 2023v3
  5. Start date: Nov 15, 2022 to Mar 15, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.
Trial Details
NCT Number NCT05618925
Lead Sponsor ImmunityBio, Inc.
Conditions Non Hodgkin's Lymphoma Refractory/Relapsed
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov